Search
for
Sort by
Research 30 of 1000+
- Skin toxicity determined in vitro by three-dimensional, native-state histoculture.
- Efficacy and Skin Toxicity Management with Cetuximab in Metastatic Colorectal Cancer: Outcomes from an Oncologic/Dermatologic Cooperation
- Skin toxicity of anti‐cancer therapy
- Skin toxicity caused by EGFR antagonists—An autoinflammatory condition triggered by deregulated IL‐1 signaling?
- A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor
- Targeted Treatments of Non-Small Cell Lung Cancer (NSCLC): Skin Toxicity
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- Skin Toxicity in Palliative Radiation Therapy
- Prophylaxis and Management of Skin Toxicities
- When bugs and drugs conspire: driving acneiform skin toxicity
- Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors
- IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes
- Severe skin toxicity during whole-brain radiotherapy, targeted therapy, and additional drug intake including St. John’s wort skin oil
- Non-Rash Skin Toxicities Associated with Novel Targeted Therapies
- IMMUNE-RELATED SKIN TOXICITIES TO CHECKPOINT INHIBITORS THERAPY
- The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus
- Management of Skin Toxicities in Cancer Treatment: An Australian/New Zealand Perspective
- Morphological characteristics and notes of the skin in preclinical toxicity assessment
- Scientific Opinion on the substantiation of health claims related to soy isoflavones and protection of DNA, proteins and lipids from oxidative damage (ID 1286, 4245), maintenance of normal blood LDL cholesterol concentrations (ID 1135, 1704a, 3093a), reduction of vasomotor symptoms associated with menopause (ID 1654, 1704b, 2140, 3093b, 3154, 3590), maintenance of normal skin tonicity (ID 1704a), contribution to normal hair growth (ID 1704a, 4254), “cardiovascular health” (ID 3587), treatment …
- Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
- Targeted Therapy– and Chemotherapy-Associated Skin Toxicities: Systematic Review and Meta-Analysis
- Effect of adenosine triphosphate on ribociclib-induced skin toxicity in rats
- Scalp Pustule as a Manifestation of Erlotinib-Induced Skin Toxicity: Report of Two Cases and Literature Review
- Protective effects of wheat sprouts extract against acrylamide-induced skin toxicity: Modulation of oxidative stress, apoptosis, and histomorphometric alterations in rats
- Abemaciclib-Associated Skin, Hair, and Nail Toxicities: A Case Report
- Understanding, recognizing, and managing toxicities of targeted anticancer therapies
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy
- Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment
- Management of Dermatologic Toxicities